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ABSTRACT
Motivation: High-throughput sequencing platforms are increasingly
used to screen patients with genetic disease for pathogenic
mutations, but prediction of the effects of mutations remains
challenging. Previously we developed SAAPdap (Single Amino Acid
Polymorphism Data Analysis Pipeline) and SAAPpred (Single Amino
Acid Polymorphism Predictor) that use a combination of rule-based
structural measures to predict whether a missense genetic variant is
pathogenic. Here we investigate whether the same methodology can
be used to develop a differential phenotype predictor, which, once
a mutation has been predicted as pathogenic, is able to distinguish
between phenotypes — in this case the two major clinical phenotypes
(hypertrophic cardiomyopathy, HCM, and dilated cardiomyopathy,
DCM) associated with mutations in the beta-myosin heavy chain
(MYH7) gene product (Myosin-7).
Results: A random forest predictor trained on rule-based structural
analyses together with structural clustering data gave a Matthews’
correlation coefficient (MCC) of 0.53 (accuracy, 75%). A post hoc
removal of machine learning models that performed particularly badly,
increased the performance (MCC=0.61, Acc=79%). This proof of
concept suggests that methods used for pathogenicity prediction can
be extended for use in differential phenotype prediction.
Contact: andrew@bioinf.org.uk –or– andrew.martin@ucl.ac.uk
Supplementary Information: supfigtab.pdf;
SupplementaryFile1.xls; SupplementaryFile2.txt;
SupplementaryFile3.pdf.
1 INTRODUCTION
Mutations in proteins generally result in loss of function, but in
some cases can lead to a gain of function. Generally this is not
gain of a novel function, but an increased activity, often through
loss of some type of control mechanism. In general, predictors of
pathogenicity do not try to distinguish between loss-of-function and
gain-of-function mutations, but simply predict whether or not there
will be some effect on function leading to a pathogenic state.
∗to whom correspondence should be addressed
In some cases however, the situation is more complex, with
mutations in a single protein leading to a number of distinct
phenotypes. For example, inherited heart muscle diseases, or
cardiomyopathies, which are a major cause of sudden cardiac death
in the young and an important cause of heart failure at all ages
(Hughes andMcKenna, 2005) are, as a group, very heterogeneous in
genotype and phenotype. Radically different phenotypes can result
from mutations in the same gene (Arad et al., 2002).
The widespread application of Single Nucleotide Polymorphism
(SNP) chips and high-throughput sequencing has generated an
urgent need for informatics tools that can help predict the effects
of the many sequence variants that these platforms identify. More
than 20 groups have devised methods to predict whether a given
mutation will have a deleterious effect (Yue et al., 2006; Uzun
et al., 2007; Yip et al., 2004; Dantzer et al., 2005; Karchin et al.,
2005; Stitziel et al., 2004; Reumers et al., 2005; Bao et al., 2005;
Reva et al., 2011; Schwarz et al., 2010; Bromberg and Rost, 2007;
Bromberg et al., 2008; Gonza´lez-Pe´rez and Lo´pez-Bigas, 2011;
Shihab et al., 2013; Al-Numair and Martin, 2013; Li et al., 2009;
Kircher et al., 2014; Calabrese et al., 2009; Worth et al., 2011; Yates
et al., 2014), the best known methods being SIFT (Ng and Henikoff,
2003), an evolutionary method which calculates a sophisticated
residue conservation score from multiple alignment, and PolyPhen-
2 (Adzhubei et al., 2010, 2013), which uses machine learning on a
set of eight sequence- and three structure-based features. A more
complete list of methods is provided on our web site at http:
//www.bioinf.org.uk/saap/methods/. However, these
tools are generally not validated for individual diseases where
most available datasets are too small to train machine-learning
methods and tend to be heavily unbalanced. An additional problem
is that it is often very difficult to obtain reliable validated data
on neutral mutations. One of the few cases where a predictor has
been produced for an individual class of proteins is the work on
voltage-gated potassium channels by Stead et al. (2011).
Attempting to distinguish between mutations in a single
protein that result in different pathogenic phenotypes is a
difficult problem that, unlike pathogenicity prediction, has not
been widely addressed. There have been a small number of
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attempts to distinguish loss-of-function and gain-of-function
mutations at a molecular level, but (as stated above) typically
gain-of-function mutations result from loss of regulation
making the protein constitutively active. For example,
mutations that cause the VAB-1 tyrosine kinase to become
constitutively active cause severe axon defects (Mohamed and
Chin-Sang, 2006). Some of the challenges in the ‘Comparative
Assessment of Genome Interpretation’ (CAGI) experiment have
required the prediction of the level of enzyme activity (e.g.
genomeinterpretation.org/content/4-NAGLU)
and some have been related to familial
combined hyperlipidemia or channelopathies
(genomeinterpretation.org/content/FCH,
genomeinterpretation.org/content/scn5a), but, to
our knowledge, there have been no clear cases where predictions
have focused on mutations in the same protein resulting in
different phenotypes other than through loss of function vs. loss of
regulation.
Initially our own focus was on trying to understand the effects
that mutations have on protein structure and then to use this
information to compare the effects of non-pathogenic mutations
and pathogenic deviations (Hurst et al., 2009). Our approach has
been to map mutations onto protein structure and to perform a rule-
based analysis of the likely structural effects of these mutations
in order to ‘explain’ the known functional effect (if any) of the
mutation. Since we map mutations to structure, we only consider
mutations in proteins for which a structure has been solved. With the
recent growth in the amount of mutation data, we have moved from
updating a database of analysis of mutations, to providing a server
(SAAPdap — Single Amino Acid Polymorphism Data Analysis
Pipeline) for analysis of the effects of mutations (http://www.
bioinf.org.uk/saap/dap/) (Al-Numair and Martin, 2013).
The approach has been used to study structural differences between
disease-causing mutations and neutral polymorphisms (Hurst et al.,
2009; Al-Numair and Martin, 2013), and to analyse mutations in
glucose-6-phosphate dehydrogenase (Kwok et al., 2002) and in the
tumour suppressor P53 (Martin et al., 2002).
While SAAPdap uses a combination of rule-based structural
measures to assess whether a mutation is likely to alter the local
structural environment, we have also developed SAAPpred (Single
Amino Acid Polymorphism Predictor) which exploits the results of
the structural analysis and uses a Random Forest machine-learning
method to predict whether mutations are pathogenic (Al-Numair
and Martin, 2013). SAAPpred is restricted to analyzing mutations
in proteins for which a native structure is available, but appears
to outperform methods such as SIFT (Ng and Henikoff, 2003),
PolyPhen-2 (Adzhubei et al., 2010, 2013) and FATHMM (Shihab
et al., 2013).
In this paper we investigate whether having predicted a mutation
as being pathogenic, the approach that we developed for SAAPdap
and SAAPpred can be used for differential phenotype prediction,
specifically for mutations in the beta-myosin heavy chain (Myosin-
7, UniProtKB/SwissProt accession P12883, http://www.
uniprot.org/uniprot/P12883), encoded by the MYH7
gene (OMIM *160760). Mutations in MYH7 lead to a number of
phenotypes, the most common being hypertrophic cardiomyopathy
(HCM, OMIM #192600) and dilated cardiomyopathy (DCM,
OMIM #613426). The numbers of mutations available for other
phenotypes are very small and consequently, for this proof-of-
concept paper, we have attempted to distinguish just between HCM
and DCM.
Myosin-7 is part of the force-generating molecular motor of the
sarcomere and parts of the structure have been solved. It is divided
into three main domains as shown in Figure S1: a globular ‘head’,
which includes the ATP-binding site and the actin-binding site; the
‘neck’ which is composed of an α-helical domain to which the
myosin light chains bind and which is further subdivided into a
converter region and a lever arm involved in the amplification of
mechanical energy; and the ‘tail’ or ‘rod’ region. Together with
MYBPC3 (the gene encoding myosin binding protein C), mutations
in MYH7 are the major cause of HCM as well as being a cause
of DCM and left ventricular non-compaction (LVNC) (Haas et al.,
2014). In contrast to MYBPC3, where most pathogenic variants
cause mRNA and protein truncation, the large majority of MYH7
variants are missense (Carrier et al., 1997; Richard et al., 2003)
which often makes prediction of pathogenicity problematic (Walsh
et al., 2010; Kumar et al., 2013).
2 MATERIALS AND METHODS
2.1 Dataset of variants
A dataset of MYH7 variants was built from a) disease-causing or
likely-pathogenic variants for which phenotypic data are available
in the Human Genome Mutation Database (HGMD) (Stenson
et al., 2002); b) variants found in a curated dataset extracted
from the literature and used for commercial gene testing reports
(Health in Code SL); and c) variants detected in a cohort of
consecutively evaluated unrelated HCM/DCM patients at the UCLH
Heart Hospital. Genetic analysis was approved by the UCLH
review board (IRB) and informed written consent was obtained
from all subjects (Lopes et al., 2013). Although there are no
co-segregation data or functional studies that can ‘prove’ the
causality of mutations, selected variants from all three datasets
were rare as defined by a minor allele frequency (MAF) < 0.5%
in the ESP6500 NIH Heart, Lung and Blood Institute (NHLBI)
exome sequencing project database (Pan et al., 2012; Andreasen
et al., 2013). Consequently as it is not possible to know whether
variants are truly pathogenic, we treat mutations associated with an
HCM or DCM cardiomyopathy phenotype in the above-mentioned
databases, or in the literature, as actual positives. This dataset is
larger and more comprehensive than the data available from other
sources and contains approximately twice the number of Myosin-
7 mutations available in Swissvar/Humsavar. The complete dataset
has been provided as SupplementaryFile1.xls. Proprietary
data from HGMD, where the mutations are not available in other
datasets, have been indicated solely by their HGMD accession code.
The numbers of mutations for each phenotype are summarized in
Table S2.
A total of 395 unique mutations (i.e. distinct mutations, different
from one another at the protein level) were identified in the MYH7
gene. More than two-thirds of them have previously been published
in the literature as being associated with disease and the others are
novel variants. Since we map mutations to protein structure and
therefore require a structure to be solved of the protein of interest,
we are not able to analyse all mutations. Of the 395 mutations,
157 (39.7%) did not map to structure and therefore could not be
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analysed (see Table S2). This situation should improve as further
structures become available. 382 of the 395 unique mutations had a
recorded phenotype and of these 228 mapped to at least one Protein
DataBank (PDB) chain. Table S3 lists the PDB structures that were
identified for human Myosin-7. When preparing the dataset in 2014,
five structures were available and three (PDB IDs: 2fxm, 2fxo and
4db1) were used in this work. The two other structures (IDs: 1ik2
and 3dtp) were eliminated since 1ik2 is a theoretical model and
3dtp is a human-chicken fusion protein. Preliminary experiments
that included this fusion protein, which covers the same region as
2fxm and 2fxo, degraded the results. Since this dataset was built,
a number of other structures have become available in the PDB
— some very recently — all but one of which map to the myosin
tail (see Figure S1), but all are also chimeric fusion proteins (see
Table S3). Consequently none of these structures has been included
at this stage.
Most mutations were associated with HCM (n = 290), whereas
all other phenotypes were associated with fewer than 50 mutations
each, including DCM with the next highest number of mutations
(n = 46). Of the unique HCM and DCM mutations, 190 and 21
respectively mapped to structure (see Table S2). Since mutations
related to these phenotypes were the most abundant, for this proof
of concept, further analyses were restricted to HCM and DCM,
grouping the remaining phenotypes as ‘other’.
2.2 SAAPdap structural analysis and SAAPpred
Our previous software, SAAPdap (Al-Numair and Martin, 2013)
performs a set of 14 structural analyses (using software written
in Perl and C), plus the calculation of solvent accessibility (Lee
and Richards, 1971). SAAPdap provides cutoffs for each of the
analyses to suggest whether these are likely to be damaging
(Hurst et al., 2009; Al-Numair and Martin, 2013). To predict
pathogenicity, a total of 47 features are derived from these analyses
(Table S1) and are used as input to SAAPpred, a machine learning
method that uses Random Forests to predict whether a mutation is
pathogenic (Al-Numair and Martin, 2013). In this paper, the same
methodology is used but, rather than using a dataset of pathogenic
and phenotypically silent mutations, a dataset of HCM and DCM
mutations in Myosin-7 is used.
2.3 A machine-learning approach for MYH7
differential phenotype prediction
As described above, for machine learning, all mutations associated
with multiple phenotypes, or causing phenotypes other than HCM
or DCM were discarded leaving 190 unique HCM and 21 unique
DCM mutations which map to structure (Table S2).
Using the results of the SAAPdap structural analysis described
above, of the 47 features used to describe the mutations, 14
were found to be redundant (i.e. they had the same value for all
examples in the dataset: the 13 UniProtKB/SwissProt features and
the disulphide (SSGeom) analysis), thus reducing the number of
informative features to 33.
Since multiple structures have been solved for MYH7, for a
given mutation, the numeric values of the features derived for
each version of the structure can be slightly different. Although a
single structure was used with SAAPpred, because of the limited
size of the available dataset for differential phenotype prediction,
it was desirable to exploit the variability in multiple structures to
expand and enrich the dataset. PDB files 4db1 and 2fxm contain
two copies of the protein while 2fxo contains four copies. For
each mutation, the feature vectors, defined from analysis of the
structure, were described using the Weka Attribute-Relation File
Format (ARFF). These data were then used to train Random Forest
predictors implemented in WEKA version 3.6.7 (Witten et al.,
2011).
The Weka Random Forest gives a classification based on a jury
vote from the trees and produces a confidence score which is the
fraction of trees that gave that prediction. Thus the confidence score
is always between 0.5 and 1.0. In the prediction phase, the scores
for the two classes are averaged separately and the higher average
score is selected as the prediction. The confidence scores were then
rescaled to run from −1.0 (DCM) to +1.0 (HCM).
The parameter space described by the number of features used
in each tree decision point (mtry) and the number of trees (T ) was
explored to find the best parameters for machine learning.
2.4 Cross-validation
A given mutation has multiple feature vectors describing the
mutation in different copies of the structure. From the machine-
learning perspective, each is a separate data point. Thus the use
of multiple structures for each mutation meant that cross-validation
could not be performed within WEKA since it is possible that
WEKA could select the same mutation (in a different structure) to
be in both training and testing sets.
To address the cross-validation problem and to deal with the
severe imbalance of the dataset (there being many more HCM
mutations than DCM), Perl code was written to limit the size of each
class by selecting examples at random and to divide the 190 HCM
and 21 DCM unique mutations with available PDB structures into
sets of approximately the same size. For example, if the data were
split into 21 sets, each of these 21 sets in turn (each containing one
DCM mutation) was chosen as a test set and the remaining 20 sets
(each containing the remaining 20 DCMs) were used for training.
In each case, the data sets were enlarged with all the available PDB
chain structures and balanced training datasets were generated by
retaining all the DCM mutations and randomly drawing the same
number of mutations from the HCM dataset. The random draws
from the HCM dataset were taken 10 times over to provide a
representative sample of the HCM class and the results from the
trained predictors were averaged.
2.5 Structural clustering of mutations
Anecdotal evidence suggested that HCM- and DCM-associated
mutations tend to be distributed differently across the Myosin-
7 structure. This observation was exploited to provide additional
features for the machine learning.
PDB files 2fxm and 2fxo, which represent the C-terminal
region, contain only two DCM mutations compared with 35 HCM,
indicating that DCM mutations are very rare in this domain. For
the N-terminal domain (PDB file 4db1), the Cα positions of the
mutated residues were clustered using single linkage hierarchical
clustering. For each of 2. . . 10 clusters, a χ2 test was performed to
see how well the clustering separated HCM from DCM mutations.
As described in the Results, three clusters have the best significance
for the clustering.
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To use this information in machine learning, the centroid of each
cluster was calculated and the feature vector for each mutation was
expanded by the addition of the three distances from the C-alpha
of the mutated residue to each of the three centroids. Mutations
that were in the C-terminal domain (and mapped to PDB files
2fxm and 2fxo rather than 4db1) were given distances of 100.0A˚,
100.0A˚, 100.0A˚ from the three clusters. To use this information in
the Random Forests, these three additional features were added to
the feature vectors in the ARFF files.
2.6 Optimizing the machine learning: feature selection
As well as using the full set of 33 non-redundant features from
SAAPdap (the ‘All’ set) with or without the three clustering
features, five reduced feature sets were explored. The first two of
these were chosen to change the way that voids are treated, while
the remaining sets were generated using feature selection to identify
the most informative features.
• All is the full set of 33 informative features (47 from
SAAPdap, but with the 14 redundant features, which were
identical for all mutations, removed): BuriedCharge, Binding,
CorePhilic, CisPro, Clash, Glycine, HBond, ImPACT,
Interface, MutantLargestVoid1. . .MutantLargestVoid10,
NativeLargestVoid1. . .NativeLargestVoid10, Proline,
RelAccess, SurfacePhobic, Void. (See Table S1 for
explanation of the feature names.)
• Top 5 voids uses the top five largest voids (before and after
mutation) instead of the standard top 10: BuriedCharge,
Binding, CorePhilic, CisPro, Clash, Glycine, HBond, ImPACT,
Interface, MutantLargestVoid1. . .MutantLargestVoid5,
NativeLargestVoid1. . .NativeLargestVoid5, Proline,
RelAccess, SurfacePhobic, Void.
• Delta Voids uses the differences in the sizes of the
top 10 voids in native and mutant structures rather
than absolute values: BuriedCharge, Binding, CorePhilic,
CisPro, Clash, Glycine, HBond, ImPACT, Interface,
DeltaLargestVoid1. . .DeltaLargestVoid10, Proline, RelAccess,
SurfacePhobic, Void.
• Set1 uses the three features from the ‘All’ set found,
individually, to be most discriminatory together with the
relative solvent accessibility. A χ2 test was performed applying
the default ‘damaging’ threshold (Al-Numair and Martin,
2013) to each feature to determine how well the feature
could separate mutations associated with HCM and DCM.
See Table S4. The three most informative features were
found to be residue conservation, mutations affecting glycine
residues and those affecting residues involved in specific
binding interactions. Accessibility was also included since our
observations of the clustering of HCM and DCM residues
showed clear differences in accessibility within the clusters.
Thus the feature set used was: Binding, RelAccess, ImPACT
and Glycine.
• Set2 was generated using the ‘BestFirst’ feature selection
method within Weka. The ‘BestFirst’ algorthm searches the
space of attribute subsets by greedy hillclimbing augmented
with backtracking. The feature set based on feature selecting
from the ‘All’ set was: Binding, RelAccess, SurfacePhobic,
CorePhilic, TotalVoidVolume, MutantLargestVoid,
NativeLargestVoid, Clash, Proline, CisPro.
• Set3 was also generated using the ‘BestFirst’ feature selection
but on the ‘Delta Voids’ set. Selected features were: Binding,
Interface, RelAccess, ImPACT, Hbond, BuriedCharge,
DeltaVoidTotal, DeltaVoidLargest1. . . DeltaVoidLargest5,
Clash, Glycine.
Initially, the number of machine-learning models was tested using
the full feature set (‘All’), plus those feature sets that reduced the
amount of void data (‘Top 5 voids’ and ‘Delta voids’), with and
without the clustering features. Having established that 11 models
was the most effective, the reduced feature sets were explored using
a smaller value of mtry owing to the much reduced number of
features.
2.7 Control experiments
Three control experiments were performed to ensure that the use
of structural information in addition to sequence information or
clustering was worthwhile.
First, to demonstrate improved prediction over a simple sequence-
based predictor, a set of control experiments was run using
only features derived from sequence data. These experiments are
described in detail in SupplementaryFile3.pdf. Briefly,
two different amino acid encodings were used, with and without
conservation score, residue number (since position in the sequence
can be regarded as a proxy for domain information, given that it is
known that some phenotypes correlate with certain domains) and
contextual information (one, three or five amino acids either side of
the mutated residue). In total, 10 feature sets were considered and
for each, four experiments were performed using different machine
learning approaches.
Second, to ensure that the performance of the predictor does
not come only from the structural clustering, we also tested the
performance using the structural clusters alone. Using the 2–10
structural clusters described above, each cluster was assigned as
a DCM or HCM cluster based on that phenotype having a higher
observed/expected ratio in that cluster. An additional cluster was
created to represent the mutations that map to the C-terminal domain
(PDB code 2fxm or 2fxo) which has a very small number of DCM
mutations. Each mutation was then predicted as DCM or HCM
based on its cluster membership. For a real prediction problem,
cluster membership would need to be assigned based on the distance
to the closest cluster centre (average linkage) or closest cluster
member (single linkage). Performance was then calculated for each
level of clustering.
Finally, as a control on the overall prediction, the testing was
repeated using two of the test sets, but the labels were randomly
shuffled five times over.
3 RESULTS
3.1 MYH7 mutation data analysis and prediction of
pathogenicity
The distribution of the variants amongst the structural and
functionally-annotated domains of the beta-myosin heavy
chain protein was analysed. Figure S1 shows the regions
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SAAPdap Structural Analysis Number of mutations
Individual significant structural effect 55
At least one significant structural effect 175
• HBond 42
• BuriedCharge 31
• SProtFT 2
• Interface 48
• Clash 14
• Proline 2
• ImPACT 138
• Binding 20
• Void 0
• SurfacePhobic 15
• Glycine 8
• CisPro 1
• CorePhilic 26
• SSGeom 0
Table 1. SAAPdap Structural Analysis for the 228 unique Myosin-7
mutations with a recorded phenotype which mapped to structure (see
Table S2).
for which structures are known and the distribution of
observed mutations together with the domains of the Myosin-7
sequence as annotated by UniProtKB/SwissProt (UniProt
Consortium, 2014) (http://www.uniprot.org/
uniprot/P12883#section_features), Pfam (Finn et al.,
2014) (http://pfam.xfam.org/protein/P12883),
SMART (Letunic et al., 2012) (http://smart.embl.
de/smart/show_motifs.pl?ID=P12883),
and InterPro (Hunter et al., 2012) (http:
//www.ebi.ac.uk/interpro/protein/P12883). All
of the 238 unique variants that mapped to structure were located
in the myosin globular ‘head’ domain or the ‘neck’ region with
no mutations seen in the ‘tail’ or ‘IQ motif’ regions. 99.1% of
mutations were in annotated domains or regions, while just two
mutations (0.9%, at positions 82 and 838) were in un-annotated
parts of the sequence. The numbers of HCM and DCM mutations
seen in each of the annotated domains are shown in Table S5.
The individual structural effects for the 228 unique mutations
which mapped to structure and for which a phenotype was also
recorded (see Table S2) were analyzed using SAAPdap. 175 variants
(76.8%) had one or more individual structural effects classified
as likely to be damaging by the individual SAAPdap analyses
while, for 55 variants, no significant individual structural effect
was detected (see Table 1). The features affected most frequently
were: mutation of a highly conserved residue (ImPACT) occurring
in 138 variants; mutation of an interface amino acid occurring in 48
variants; and disruption of hydrogen-bonds occurring in 42 variants.
Other significant mutation effects occurred less frequently, with no
observed mutations causing voids.
Before attempting to perform differential phenotype prediction,
it would be necessary to predict that a mutation is pathogenic. The
output from SAAPdap for the 228 unique mutations that mapped to
structure was fed into SAAPpred (Al-Numair and Martin, 2013) and
93.0% of mutations were predicted as pathogenic (i.e. Sn=0.930).
This compares with 69.51% predicted to be pathogenic using SIFT
Number of
folds / models T mtry Acc MCC
10 1000 10 0.6229 0.2463
10 1000 15 0.6750 0.3590
10 1000 20 0.7000 0.4103
10 1000 25 0.6916 0.3851
10 50 20 0.6833 0.3681
10 100 20 0.6916 0.3872
10 500 20 0.6937 0.4023
10 1000 20 0.7000 0.4103
10 2000 20 0.6812 0.3686
10 5000 20 0.7000 0.4005
Table 2. Exploring the number of features and number of trees in HCM vs.
DCM prediction. T is the number of trees;mtry is the number of randomly
chosen attributes in every split. Initially mtry was explored using T =
1000 and an optimum value of 20 was identified (shown in bold). T was
then explored retaining the optimum value of 1000. Performance measures:
accuracy (Acc) and Matthews’ correlation coefficient (MCC). All scores are
averaged over 10-folds of ‘manual’ (non-WEKA) cross-validation.
and 90% predicted to be pathogenic using PolyPhen-2. Other
metrics such as specificity (Sp), accuracy (Acc), the F1-score
and the Matthews’ Correlation Coefficient (MCC) could not be
calculated since no set of validated non-pathogenic single amino
acid mutations is available — even in the ESP 5K and 1000
Genomes data there are very few missense variants in MYH7 with
a frequency > 5% that could comfortably be classified as benign.
3.2 Initial machine learning results for differential
phenotype prediction
As described in the Materials and Methods, machine learning
was performed using random forests implemented in Weka with
the 33 non-redundant features from SAAPdap structural analysis
(Table S1). Since each mutation mapped to multiple structures,
cross-validation was performed outside Weka to ensure that the
same mutation was not included in the training and testing sets (but
mapped to different structures). The parameter space described by
the number of features used in each tree decision point (mtry) and
the number of trees (T ) was explored and, as shown in Table 2,
the best results were obtained using 1000 trees with 20 features
(accuracy of 70% and MCC=0.41).
3.3 Structural clustering of mutations
As described in the Materials and Methods, the Cα positions of the
mutated residues were clustered using single linkage hierarchical
clustering and a χ2 test was performed for each of 2. . . 10 clusters, to
see how well the clustering separated HCM from DCM mutations.
Results are shown in Table 3. Apart from two clusters, these are all
clearly significant at the p < 0.05 level. However, as the number
of clusters gets larger, one needs to take care with the significance
levels, because no more than 20% of expected values should be< 5
and none < 1 (significance will be over-estimated if either of these
is true). For ≥ 4 clusters, the first of these fails and for ≥ 6 clusters
the second also fails. However, between three and six clusters the
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Number Percentage of
of clusters Significance Expecteds < 5
2 p < 0.4384 0
3 p < 0.0003755 16.7%
4 p < 0.001256 37.5%
5 p < 0.002577 50%
6 p < 0.005057 50%
7 p < 0.01013 50%
8 p < 0.01778 56.25%
9 p < 0.03044 55.56%
10 p < 0.03116 60%
Table 3. Significance calculated fromχ2 tests on the ability of 3D clustering
to separate HCM from DCM mutations. The highest significance result is
shown in bold. For the p-value to be reliable, there must be no more than
20% of expected counts less than five. Consequently the p-values for ≥ 4
clusters will be over-estimated.
Fig. 1. Clustering Myosin-7 mutations in the N-terminal region using PDB
file 4db1. For the three clusters, HCM mutations are shown in 1: red, 2:
green and 3: blue, while DCM mutations are shown in 1: orange, 2: yellow
and 3: cyan. DCM mutations are over-represented in cluster 3 (cyan); when
they appear in clusters 1 and 2, (orange and yellow) they are mostly buried.
significance is so good, that (while it will be over-estimated for 4–
6 clusters) it is clearly still better than p < 0.05 with 3 clusters
passing both of the validity criteria and giving a highly significant
result even if a Bonferroni correction is made for multiple testing.
Consequently we clearly have clusters of residues in the N-terminal
region that are over/under populated with DCM and HCMmutations
compared with what is expected.
Figure 1 illustrates the three clusters in the N-terminal domain
contained in PDB file 4db1. Cluster members are listed in
SupplementaryFile2.txt and shown on the sequence in
Figure S2. In particular, DCM is highly over-represented in the third
(blue/cyan) cluster. DCM mutations in clusters 1 and 2 (orange and
yellow) are hardly visible and therefore mostly buried. On the other
hand, the DCM mutations in cluster 3 (cyan) are largely on the
surface.
As a control, to ensure that the significance of the clustering was
not a random effect, we also permuted the labels randomly for the
three clusters 1000 times over and calculated the average random p-
value (p = 0.5133, σn−1 = 0.2859) from a χ
2 test. This is clearly
not significant and compares with the true labels which gave a p <
0.0003755. This p-value is 1.794 standard deviations away from the
mean on the distribution of random p-values which is significant at
the p < 0.05 level.
3.4 Optimizing the machine learning
Initial training to explore the number of trees and features
considered per decision point was performed as described in
the materials and methods using 10 machine-learning models
(equivalent to cross-validation folds, each with a random selection
of the HCM data) with the prediction results averaged across the
10. After determining the optimum number of features considered
per descision point and number of trees, the different feature subsets
were explored together with different numbers of machine-learning
models (5, 11 and 21 models). Addition of the ‘clustering’ feature
described above was also explored.
As shown in Table 4, the best performance was obtained using 11
machine-learning models with ‘Set2’ plus the clustering features.
Cross-validation with 11 models used 19 of the 21 DCMs in each
training set with 2 held back for testing. This gave an accuracy of
75% and MCC=0.531. By removing two machine-learning models
that performed particularly badly and did not predict any DCM
mutations (whether correct or incorrect), this increased to an
accuracy of 79% and MCC=0.61. It appears that these particularly
bad machine-learning models have failed to learn the characteristics
of DCM mutations. To apply the method to novel mutations, we
would remove these two bad machine-learning models and use the
remaining nine to make predictions.
3.5 Control Experiments
First, a set of 40 control experiments were performed to demonstrate
improved prediction over a simple sequence-based predictor.
Only five of the 40 experiments showed a mean MCC>0.1
with the best performance being a mean MCC=0.167 which is
clearly considerably worse than our full predictor (MCC=0.53, or
MCC=0.61 with the worst machine-learning models removed) —
See SupplementaryFile3.pdf.
Second, a control experiment was performed to ensure that
the performance of the predictor does not come only from the
structural clustering, by assigning a prediction of DCM or HCM
based purely on cluster membership. The best performance was
achieved with three clusters (plus the C-terminal domain cluster):
MCC=0.33, ACC=0.89, SnHCM=0.95, SnDCM=0.33. Clearly this
performance is considerably worse than our full predictor as judged
by MCC (full predictor MCC=0.53, or MCC=0.61 with the worst
machine-learning models removed).
This is also a good example to illustrate the well-known
problem in machine learning that accuracy is a poor indicator of
performance with unbalanced datasets (the cluster-only prediction
gives ACC=0.89 while the full predictor gives ACC=0.75, or
ACC=0.79 with the worst models machine-learning removed).
However, simply predicting everything as HCM would give
ACC=0.90 and, by definition, SnHCM=1.00 and SnDCM=0.00,
while the MCC would be a much better indicator of overall
performance giving a value ofMCC=0.12 (adding 1 to TP,FP,TN,FN
since TN=FN=0 results in a divide-by-zero error and treating HCM
as positive and DCM as negative.).
Finally, the overall prediction control experiment, shuffling the
labels on two of the test sets randomly, as expected, gave essentially
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Number
of folds Features
/ models used T mtry SnHCM SnDCM F1 Acc MCC
5 All 1000 20 0.572 0.611 0.576 0.576 0.152
5 All + Clustering 1000 20 0.755 0.481 0.679 0.648 0.311
5 Top 5 voids + Clustering 1000 20 0.735 0.611 0.688 0.681 0.368
5 10 delta void + Clustering 1000 20 0.785 0.407 0.676 0.608 0.205
11 All 1000 20 0.705 0.648 0.673 0.682 0.429
11 All + Clustering 1000 20 0.739 0.463 0.662 0.608 0.220
11 Top 5 voids + Clustering 1000 20 0.830 0.481 0.741 0.699 0.427
11 10 delta voids + Clustering 1000 20 0.830 0.519 0.730 0.676 0.521
21 All 1000 20 0.619 0.648 0.585 0.631 0.357
21 All + Clustering 1000 20 0.746 0.463 0.684 0.623 0.293
21 Top 5 voids + Clustering 1000 20 0.690 0.463 0.610 0.627 0.374
21 10 delta voids + Clustering 1000 20 0.619 0.426 0.584 0.560 0.133
11 Set1 + Clustering 1000 5 0.659 0.593 0.603 0.625 0.314
11 Set2 + Clustering 1000 5 0.795 0.574 0.737 0.750 0.531
11 Set3 + Clustering 1000 5 0.852 0.519 0.746 0.699 0.520
Table 4. Summary results of machine learning performance using different features of HCM/DCM dataset and using different numbers of folds of cross-
validation. The best performing predictor is shown in bold. (T : the number of trees;mtry : the number of randomly chosen attributes in every split; SnHCM :
Sensitivity for HCM mutations; SnDCM : Sensitivity for DCM mutations; F1: The F1-score; Acc: Accuracy; MCC: Matthews’ Correlation Coefficient)
random prediction performance with an MCC=−0.123 for the first
test set and MCC=−0.115 for the second test set.
4 DISCUSSION
It is logical to assume that the functional consequences of mutations
in the same gene depend on the specific domain or region where
the variant is localized (Woo et al., 2003), but the hypothesis that
the structural impact of a missense variant influences differential
pathogenic phenotype or outcome has not previously been tested.
In practice, a novel mutation would be tested for predicted
pathogenicity before an HCM/DCM prediction was performed. We
confirmed that the SAAPpred approach performs well in identifying
pathogenic mutations in MYH7 and went on to test a machine-
learning method that discriminated between pathogenic variants
associated with an HCM or DCM phenotype (accuracy of 75% and
MCC=0.531). This was achieved by averaging 11 machine-learning
models using feature Set2 (Binding, RelAccess, SurfacePhobic,
CorePhilic, Voids, MutantLargestVoid1, NativeLargestVoid1,
Clash, Proline, CisPro and Clustering) and using 1000 trees
with 5 features. These differential phenotype prediction results
are surprisingly good considering the limited size of the dataset
used in training. Indeed the results are as good as the overall
performance of some methods used for general pathogenicity
prediction — for example, our assessment (Al-Numair and Martin,
2013) of MutationAssessor showed an overall accuracy of 69.8%
and MCC=0.453, while SIFT showed an overall accuracy of 76.3%
and MCC=0.528. Clearly these results are comparable with what we
are able to achieve for HCM/DCM differential phenotype prediction
which is a more difficult problem owing to the small unbalanced
dataset. By removing two machine-learning models that performed
particularly badly, the performance was increased to an accuracy of
79% and MCC=0.61.
Because the SAAPdap structural analysis relies on having a
crystal structure of the protein in question, our predictions are
limited to mutations in regions of the protein for which a structure
has been solved. Consequently, we are only able to look at 190
of 290 unique mutations leading to HCM and 21 of 46 mutations
leading to DCM. As structures become available for more of the
protein, then this situation will improve and some new structures
have become available since our dataset was built. However,
for mutations that are present in disordered regions of structure,
different methods of prediction will be required. It is also possible
that the performance of the method may be further improved by
taking into account missing parts of the structure. However, since all
the structural parameters included in the prediction are the results of
local interactions, this is unlikely to have a significant effect.
Our analysis of the structural distribution of HCM- and DCM-
associated mutations showed that there was a highly statistically
significant difference in the locations of these mutations. Referring
to Figures 1 and S2 , DCM is highly over-represented in the
blue/cyan cluster and largely on the surface, while DCM mutations
present in the remaining clusters are mostly buried. The functional
consequences of this distribution warrant further in vitro studies.
4.1 Conclusions and future directions
Missense single nucleotide variants in MYH7 lead to a dominant
negative effect in which the mutated protein is not degraded
but rather integrates into the sarcomere, leading to the disease
phenotype. The various effects of individual variants on fibre
contractile velocity, force and calcium sensitivity have been
proposed as an explanation for the existence of dramatically
7
Al-Numair et al.
different phenotypes arising from genetic variation in the same
molecule. A paradigm has been proposed whereby mutations that
increase motor activity and power output lead to HCM, while those
that diminish motor function and decrease power output lead to
DCM (Spudich, 2014).
Our SAAPpred predictor currently relies on having a structure
available for the protein in question, but planned enhancements
include the use of modelled structures where no experimental
structure is available and exploitation of structural information from
homologues. In the same way, we plan to expand the data points for
our differential phenotype predictor by including information from
homologous proteins. In future work, we will also explore the newly
available chimeric structures to see if they can be used for prediction
of additional mutations.
As more mutation data become available, we also intend to
integrate a validated pathogenicity predictor with a three-class
differential phenotype predictor (HCM vs. DCM vs. other) although
there is no a priori reason to believe that all ‘other’ mutations will
have shared properties, or indeed that they will have properties that
are very different from HCM or DCM. As a preliminary experiment,
we selected 10 ‘other’ mutations (some collected after the main
dataset was built) at random and found that nine of them were
predicted as pathogenic using SAAPpred. If the properties of these
mutations are significantly different from HCM and DCM we might
expect the confidence scores provided by the differential phenotype
predictor to be very low. We analyzed all 10 mutations and found
that eight were predicted as HCM and two as DCM. For two
of the HCM predictions (including the one predicted as SNP by
SAAPpred), the confidence score was indeed very low (<0.05), but
for the others, the confidence was >0.3, typical of other predictions
(see Table S6). Nonetheless, we intend to explore this further.
This work confirms the hypothesis that structural data can be
used with machine learning to create a differential phenotype
predictor, in this case able to distinguish between HCM and DCM
mutations in MYH7. The performance exceeds that of the well-
known SIFT program in the problem of predicting pathogenic vs.
neutral mutations. Differential phenotype prediction has all the
challenges of pathogenicity prediction with the added complications
of having a small unbalanced dataset. This work provides the basis
for differential phenotype prediction and with further work could be
used to guide clinical genetic testing strategies and further clinical
investigations.
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